<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859038</url>
  </required_header>
  <id_info>
    <org_study_id>SGOG OV4B</org_study_id>
    <secondary_id>SOC 2</secondary_id>
    <nct_id>NCT02859038</nct_id>
  </id_info>
  <brief_title>Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)</brief_title>
  <acronym>SUNNY</acronym>
  <official_title>Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to answer the fundamental question, should the physicians choose
      Surgery or Chemotherapy (SOC 2) in advanced ovarian cancer?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Compare the efficacy and safety in patients with FIGO (2014) stage IIIC or IV
      epithelial ovarian cancer, fallopian tube cancer, or peritoneal carcinoma treated with
      neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery.

      OUTLINE: This is a randomized phase III multicenter study. Patients will receive upfront
      maximal cytoreductive surgery followed by at least 6 cycles of adjuvant chemotherapy or 3
      cycles of neoadjuvant chemotherapy followed by interval debulking surgery, and then at least
      3 cycles of adjuvant chemotherapy.

      Patients are followed every 3 months within the first 5 years, and then every 6 months.

      PROJECTED ACCRUAL: A total of 456 patients will be accrued for this study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed for at least 5 years after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Participants will be followed for at least 2 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>Participants will be followed up to 6 months after randomization</time_frame>
    <description>The surgical complications will be evaluated at 30-day after upfront cytoreductive surgery or interval debulking surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Participants will be followed for at least 5 years or death after randomization</time_frame>
    <description>QOQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Upfront cytoreductive surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upfront cytoreductive surgery</intervention_name>
    <description>Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5</description>
    <arm_group_label>Upfront cytoreductive surgery</arm_group_label>
    <other_name>Primary debulking surgery, PDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interval debulking surgery</intervention_name>
    <description>3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥ 18 years.

          2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube
             cancer or primary peritoneal carcinoma (diagnosis by biopsy or fine needle
             aspiration*). Laparoscopic biopsy with pictures is recommended.

             * If fine needle aspiration showing an adenocarcinoma, patients should satisfy the
             following conditions: a. the patient has a pelvic mass, and b. omental cake or other
             metastasis larger than 2 cm in the upper abdomen, or pathologic confirmed
             extra-abdominal metastasis, and c. serum CA125/CEA ratio&gt;25. If serum CA125/CEA
             ratio&lt;25 or malignancies of other origins, such as breasts and digestive tract, are
             suspected from symptoms, physical examinations or imaging diagnosis, endoscopy or
             ultrasonography should be done to exclusive metastasis ovarian cancer.

          3. ECOG performance status of 0 to 2.

          4. ASA score of 1 to 2.

          5. Adequate bone marrow, liver and renal function to receive chemotherapy and
             subsequently to undergo surgery:

               1. white blood cells &gt;3,000/µL, absolute neutrophil count ≥1,500/µL, platelets
                  ≥100,000/µL, hemoglobin ≥9 g/dL,

               2. serum creatinine &lt;1.25 x upper normal limit (UNL) or creatinine clearance ≥60
                  mL/min according to Cockroft-Gault formula or to local lab measurement,

               3. serum bilirubin &lt;1.25 x UNL, AST(SGOT) and ALT(SGPT) &lt;2.5 x UNL.

          6. Comply with the study protocol and follow-up.

          7. Written informed consent.

        Exclusion Criteria:

          1. Patients with non-epithelial tumors as well as borderline tumors.

          2. Mucinous ovarian cancer.

          3. Low grade ovarian cancer.

          4. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ.

          5. Any other concurrent medical conditions contraindicating surgery or chemotherapy that
             could compromise the adherence to the protocol.

          6. Other conditions, such as religious, psychological and other factors, that could
             interfere with provision of informed consent, compliance to study procedures, or
             follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Jiang, MD</last_name>
    <phone>+862164041990</phone>
    <email>jiang.rong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, RN</last_name>
    <phone>+862164041990</phone>
    <email>yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yet-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Liu, MD,PhD</last_name>
      <phone>862087343392</phone>
      <email>liujih@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Jiang, MD</last_name>
      <phone>+862164041990</phone>
      <email>jiang.rong@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuting Luan, RN</last_name>
      <phone>+862164041990</phone>
      <email>yutingluan@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First Maternity and Infant Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xipeng Wang, MD,PhD</last_name>
      <phone>86 21 20261000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xipeng Wang, MD,PhD</last_name>
      <phone>862125078999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqing Zhu, MD</last_name>
      <phone>86 571 8822222</phone>
      <email>zjq-hz@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MyungHee Nam, RN</last_name>
      <phone>82220721922</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JinHee Kim, BSN</last_name>
      <email>koreagynonco@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

